{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T21:52:05Z","timestamp":1775771525043,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Adv Therapy"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1007\/s12325-008-0108-9","type":"journal-article","created":{"date-parts":[[2008,10,4]],"date-time":"2008-10-04T09:11:47Z","timestamp":1223111507000},"page":"1010-1018","source":"Crossref","is-referenced-by-count":18,"title":["Open experience with a new myorelaxant agent for low back pain"],"prefix":"10.1007","volume":"25","author":[{"given":"Silvana","family":"Sartini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,10,4]]},"reference":[{"issue":"suppl.1","key":"108_CR1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/rheumatology\/41.S1.3","volume":"41","author":"J.Y. Reginster","year":"2002","unstructured":"Reginster JY. The prevalence and burden of arthritis. Rheumatology. 2002;41 (suppl. 1):3\u20136.","journal-title":"Rheumatology"},{"key":"108_CR2","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1358\/dot.2004.40.9.850496","volume":"40","author":"K.C. Jackson 2nd","year":"2004","unstructured":"Jackson KC 2nd. Pharmacotherapy in lower back pain. Drugs Today (Barc). 2004;40:765\u2013772.","journal-title":"Drugs Today (Barc)"},{"key":"108_CR3","first-page":"120","volume":"50","author":"Centers for Disease Control.","year":"2001","unstructured":"Centers for Disease Control. Prevalence of disabilities and associated health conditions among adults-United States, 1999. MMWR Morb Mortal Wkly Rep. 2001;50:120\u2013125.","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"108_CR4","volume-title":"National Ambulatory Medical Care Survey: 2000 Summary. Advance Data Vital and Health Statistics","author":"D.K. Cherry","year":"2002","unstructured":"Cherry DK, Woodwell DA. National Ambulatory Medical Care Survey: 2000 Summary. Advance Data Vital and Health Statistics; No. 328. Hyattsville, MD: National Center for Health Statistics; 2002."},{"key":"108_CR5","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/BOR.0b013e3282f94256","volume":"20","author":"H. Raspe","year":"2008","unstructured":"Raspe H. Management of chronic low back pain in 2007\u20132008. Curr Opin Rheumatol. 2008;20:276\u2013281.","journal-title":"Curr Opin Rheumatol."},{"issue":"suppl.3A","key":"108_CR6","doi-asserted-by":"crossref","first-page":"20S","DOI":"10.1016\/S0002-9343(00)00682-3","volume":"110","author":"S. Hernandez-Diaz","year":"2001","unstructured":"Hernandez-Diaz S, Garcia Rodriguez LA. Epidemiological assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am J Med. 2001;110(suppl. 3A):20S\u201327S.","journal-title":"Am J Med."},{"key":"108_CR7","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/00001648-200007000-00004","volume":"11","author":"L.A. Garcia Rodriguez","year":"2000","unstructured":"Garcia Rodriguez LA, Hernandez-Diaz S. The epidemiology of myocardial infarction and heart failure among users of nonsteroidal antiinflammatory drugs. Epidemiology. 2000;11:382\u2013386.","journal-title":"Epidemiology"},{"key":"108_CR8","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1136\/bmj.322.7281.266","volume":"322","author":"G.L. Nielsen","year":"2001","unstructured":"Nielsen GL, Sorensen HT, Larsen H, Pedersen L. Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal antiinflammatory drugs: population-based observational study and case-control study. Brit Med J. 2001;322:266\u2013270.","journal-title":"Brit Med J."},{"key":"108_CR9","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/00001648-200109000-00018","volume":"12","author":"L.A. Garcia Rodriguez","year":"2001","unstructured":"Garcia Rodriguez LA, Hernandez-Diaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal antiinflammatory drugs. Epidemiology. 2001;12:570\u2013576.","journal-title":"Epidemiology."},{"key":"108_CR10","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jpain.2004.09.005","volume":"6","author":"M.E. Hale","year":"2005","unstructured":"Hale ME, Dvergsten C, Gimbel J. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo-and active-controlled phase III study. J Pain. 2005;6:21\u201328.","journal-title":"J Pain."},{"key":"108_CR11","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00002508-199909000-00004","volume":"15","author":"M.E. Hale","year":"1999","unstructured":"Hale ME, Fleischmann R, Salzman R, et al. Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain. Clin J Pain. 1999;15:179\u2013183.","journal-title":"Clin J Pain."},{"key":"108_CR12","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0885-3924(99)00079-2","volume":"18","author":"R.T. Salzman","year":"1999","unstructured":"Salzman RT, Roberts MS, Wild J, Fabian C, Reder RF, Goldenheim PD. Can a controlled-release oral dose form of oxycodone be used as readily as an immediate-release form for the purpose of titrating to stable pain control? J Pain Symptom Manage. 1999;18:271\u2013279.","journal-title":"J Pain Symptom Manage."},{"key":"108_CR13","first-page":"772","volume":"27","author":"T.J. Schnitzer","year":"2000","unstructured":"Schnitzer TJ, Gray WL, Paster RZ, Kamin M. Efficacy of tramadol in treatment of chronic low back pain. J Rheumatol. 2000;27:772\u2013778.","journal-title":"J Rheumatol."},{"key":"108_CR14","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/S0149-2918(03)80071-1","volume":"25","author":"G.E. Ruoff","year":"2003","unstructured":"Ruoff GE, Rosenthal N, Jordan D, Karim R, Kamin M. Tramadol\/acetaminophen combination tablets for the treatment of chronic lower back pain: a multicenter, randomized, double-blind, placebocontrolled outpatient study. Clin Ther. 2003;25:1123\u20131141.","journal-title":"Clin Ther."},{"key":"108_CR15","first-page":"1313","volume":"37","author":"J.K. Elenbaas","year":"1980","unstructured":"Elenbaas JK. Centrally acting oral skeletal muscle relaxants. Am J Hosp Pharm. 1980;37:1313\u20131323.","journal-title":"Am J Hosp Pharm."},{"key":"108_CR16","first-page":"331","volume":"37","author":"K. Morikawa","year":"1987","unstructured":"Morikawa K, Oshita M, Yamazaki M, et al. Pharmacological studies of the new centrally acting muscle relaxant 4\u2032-ethyl-2-methyl-3-pyrrolidinopropiophenone hydrochloride. Arzneimittelforschung. 1987;37:331\u2013336.","journal-title":"Arzneimittelforschung."},{"key":"108_CR17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1254\/jjp.73.215","volume":"73","author":"M. Matsunaga","year":"1997","unstructured":"Matsunaga M, Uemura Y, Yonemoto Y, et al. Long-lasting muscle relaxant activity of eperisone hydrochloride after percutaneous administration in rats. Jpn J Pharmacol. 1997;73:215\u2013220.","journal-title":"Jpn J Pharmacol."},{"key":"108_CR18","first-page":"459","volume":"7","author":"S. Iwase","year":"1992","unstructured":"Iwase S, Mano T, Saito M, Ishida G. Effect of a centrally-acting muscle relaxant, eperisone hydrochloride, on muscle sympathetic nerve activity in humans. Funct Neurol. 1992;7:459\u2013470.","journal-title":"Funct Neurol."},{"key":"108_CR19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1254\/jphs.FPJ03087X","volume":"95","author":"A. Sakaue","year":"2004","unstructured":"Sakaue A, Honda M, Tanabe M, Ono H. Antinociceptive effects of sodium channel-blocking agents on acute pain in mice. J Pharmacol Sci. 2004;95:181\u2013188.","journal-title":"J Pharmacol Sci."},{"key":"108_CR20","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1527-3458.2006.00218.x","volume":"12","author":"S. Farkas","year":"2006","unstructured":"Farkas S. Silperisone: a centrally acting muscle relaxant. CNS Drug Rev. 2006;12:218\u2013235.","journal-title":"CNS Drug Rev."},{"key":"108_CR21","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1124\/jpet.105.089805","volume":"315","author":"P. Kocsis","year":"2005","unstructured":"Kocsis P, Farkas S, Fodor L, et al. Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005;315:1237\u20131246.","journal-title":"J Pharmacol Exp Ther."},{"key":"108_CR22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3109\/13550289609146899","volume":"2","author":"M. Nakagawa","year":"1996","unstructured":"Nakagawa M, Nakahara K, Maruyama Y, et al. Therapeutic trials in 200 patients with HTLV-I-associated myelopathy\/tropical spastic paraparesis. J Neurovirol. 1996;2:345\u2013355.","journal-title":"J Neurovirol."},{"key":"108_CR23","first-page":"403","volume":"30","author":"K. Murayama","year":"1984","unstructured":"Murayama K, Katsumi T, Tajika E, Nakamura T. Clinical application of eperisone hydrochloride to neurogenic bladder. Hinyokika Kiyo. 1984;30:403\u2013408.","journal-title":"Hinyokika Kiyo."},{"key":"108_CR24","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/BF01300302","volume":"37","author":"Y. Kobayashi","year":"1992","unstructured":"Kobayashi Y, Kawasaki T, Yoshimi T, Nakajima T, Kanai K. Muscle cramps in chronic liver diseases and treatment with antispastic agent (eperisone hydrochloride). Dig Dis Sci. 1992;37:1145\u20131146.","journal-title":"Dig Dis Sci."},{"key":"108_CR25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3109\/03009749109096946","volume":"91","author":"M.E. Weinblatt","year":"1991","unstructured":"Weinblatt ME. Nonsteroidal antiinflammatory drug toxicity: increased risk in the elderly. Scand J Rheumatol Suppl. 1991;91:9\u201317.","journal-title":"Scand J Rheumatol Suppl."},{"key":"108_CR26","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1358\/mf.1999.21.3.534831","volume":"21","author":"K. Bose","year":"1999","unstructured":"Bose K. The efficacy and safety of eperisone in patients with cervical spondylosis: results of a randomized, double-blind, placebocontrolled trial. Methods Find Exp Clin Pharmacol. 1999;21:209\u2013213.","journal-title":"Methods Find Exp Clin Pharmacol."},{"key":"108_CR27","first-page":"202","volume":"55","author":"M. Tariq","year":"2005","unstructured":"Tariq M, Akhtar N, Ali M, Rao S, Badshah M, Irshad M. Eperisone compared to physiotherapy on muscular tone of stroke patients: a prospective randomized open study. J Pak Med Assoc. 2005;55:202\u2013204.","journal-title":"J Pak Med Assoc."},{"key":"108_CR28","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/sim.4780060603","volume":"6","author":"S.M. Snapinn","year":"1987","unstructured":"Snapinn SM. Evaluating the efficacy of a combination therapy. Stat Med. 1987;6:657\u2013665.","journal-title":"Stat Med."},{"key":"108_CR29","first-page":"125","volume":"12","author":"D.G. Borenstein","year":"1990","unstructured":"Borenstein DG, Lacks S, Wiesel SW. Cyclobenzaprine and naproxen versus naproxen alone in the treatment of acute low back pain and muscle spasm. Clin Ther. 1990;12:125\u2013131.","journal-title":"Clin Ther."},{"key":"108_CR30","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S1090-3801(02)00069-1","volume":"7","author":"T. Graven-Nielsen","year":"2003","unstructured":"Graven-Nielsen T, Jansson Y, Segerdahl M, et al. Experimental pain by ischaemic contractions compared with pain by intramuscular infusions of adenosine and hypertonic saline. Eur J Pain. 2003;7:93\u2013102.","journal-title":"Eur J Pain."},{"key":"108_CR31","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/00002517-199904000-00015","volume":"12","author":"S. Yabuki","year":"1999","unstructured":"Yabuki S, Kikuchi S, Midorikawa H, Hoshino S. Vascular backache and consideration of its pathomechanisms: report of two cases. J Spinal Disord. 1999;12:162\u2013167.","journal-title":"J Spinal Disord."},{"key":"108_CR32","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1254\/jjp.50.271","volume":"50","author":"S. Inoue","year":"1989","unstructured":"Inoue S, Bian K, Okamura T, Okunishi H, Toda N. Mechanisms of action of eperisone on isolated dog saphenous arteries and veins. Jpn J Pharmacol. 1989;50:271\u2013282.","journal-title":"Jpn J Pharmacol."},{"key":"108_CR33","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/S0140-6736(04)17514-4","volume":"364","author":"P. Juni","year":"2004","unstructured":"Juni P, Nartey L, Reichenback S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative metaanalysis. Lancet. 2004;364:2021\u20132029.","journal-title":"Lancet."},{"key":"108_CR34","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1097\/01.BRS.0000090503.38830.AD","volume":"28","author":"M.W. Tulder van","year":"2003","unstructured":"van Tulder MW, Touray T, Furlan AD, Solway S, Bouter LM. Cochrane Back Review Group. Muscle relaxants for nonspecific low back pain: a systematic review within the framework of the Cochrane collaboration. Spine. 2003;28:1978\u20131992.","journal-title":"Spine."},{"key":"108_CR35","doi-asserted-by":"crossref","first-page":"505","DOI":"10.7326\/0003-4819-147-7-200710020-00008","volume":"147","author":"R. Chou","year":"2007","unstructured":"Chou R, Huffman LH. American Pain Society. American College of Physicians. Medications for acute and chronic low back pain: a review of the evidence for an American Pain Society\/American College of Physicians clinical practice guideline. Ann Intern Med. 2007;147:505\u2013514.","journal-title":"Ann Intern Med."},{"key":"108_CR36","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.clinthera.2004.09.008","volume":"26","author":"P.P. Toth","year":"2004","unstructured":"Toth PP, Urtis J. Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone. Clin Ther. 2004;26:1355\u20131367.","journal-title":"Clin Ther."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-008-0108-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-008-0108-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-008-0108-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T03:55:52Z","timestamp":1559447752000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-008-0108-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["108"],"URL":"https:\/\/doi.org\/10.1007\/s12325-008-0108-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}